Open AccessRadioembolization for hepatocellular carcinoma using TheraSphere®
Author(s) -
Syed Qaseem Ali
Publication year - 2011
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.80388
Subject(s) - medicine , hepatocellular carcinoma , portal vein thrombosis , randomized controlled trial , brachytherapy , selective internal radiation therapy , radiology , radiation therapy , oncology , malignancy , microsphere , clinical trial , carcinoma , portal vein , chemical engineering , engineering
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y90) microspheres is a new concept in radiation therapy for HCC. This review focuses on the indications, efficacy, side effects, and future direction of Y90 therapy, using TheraSphere® , in HCC patients.